Tivic Health Files New Vagus Nerve Stimulation Patent

Therapeutics firm Tivic Health Systems Inc. has filed a new patent application with the U.S. Patent Office for its vagus nerve-related technology.

Patent No. 63,492,402, “Method and Apparatus for Electrical Stimulation of the Vagus Nerve,” expands the claims and protection around the technology in advance of potential U.S. Food and Drug Administration (FDA) approval and commercialization of Tivic’s non-invasive cervical vagus nerve stimulation (VNS) device.

“This patent for our VNS technology builds upon the findings from our sponsored research at the Feinstein Institute, which has demonstrated that tailoring key stimulation parameters to each study subject results in a meaningfully improved effect on measures of the autonomous nervous system,” Tivic Health Chief Scientific Officer Blake Gurfein said. “When compared with other technologies that apply the same stimulation approach to all patients, we believe this improvement will enable Tivic Health to develop more effective device therapies, which will be a key differentiator and create compelling use cases for the indications we plan to target.”

Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health takes a multi-pronged approach to treating the root causes of diseases caused by immune dysregulation and dysautonomia. The combination of bioelectronic and biologic medicines allow Tivic to target disorders and disease via both neural pathways and molecular approaches.

Tivic Health’s first FDA approved product, ClearUP, is proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors.